TokenPost·
Corcept Ties $3B-$5B Cushing’s Revenue Outlook to Relacorilant
The current Cushing’s syndrome business could generate at least $2 billion in annual revenue by decade’s end. The FDA is expected to decide on relacorilant by Dec. 17, 2026.
More news
- DecryptMorning Minute: CFTC Clears Stock Perps, Gets Sued the Same Day
- TokenPost[Coin record watch] XCAT among five tokens hitting record highs as 45 set new lows
- TokenPostEarly U.S. Midterm Results Favor Democrats as Asian Tech Shares Fall
- TokenPostMarqeta Guides for Q4 Gross Profit Growth of 5% to 7%, Net Revenue of 3% to 5%
- TokenPostStrategy Posts $20.9 Billion Digital-Asset Gain for Third Quarter
- Crypto BriefingBitcoin ETFs bleed $1.16 billion in three days as price holds above $76,000